DHEA Against Vaginal Atrophy - Safety Study of 12 Months
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase III trial is to assess the long-term safety of intravaginal
dehydroepiandrosterone (DHEA) in non-hysterectomized postmenopausal women with vaginal
atrophy aged 40 to 75 years.